
Nisha Singh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3023845/publications.pdf Version: 2024-02-01



NISHA SINCH

#	Article	IF	CITATIONS
1	GABAA and NMDA receptor density alterations and their behavioral correlates in the gestational methylazoxymethanol acetate model for schizophrenia. Neuropsychopharmacology, 2022, 47, 687-695.	5.4	6
2	A Reactivity-Based ¹⁸ F-Labeled Probe for PET Imaging of Oxidative Stress in Chemotherapy-Induced Cardiotoxicity. Molecular Pharmaceutics, 2022, 19, 18-25.	4.6	2
3	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet, The, 2022, 399, 36-49.	13.7	161
4	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial. Lancet, The, 2022, 399, 2212-2225.	13.7	23
5	An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females. EBioMedicine, 2022, 81, 104128.	6.1	8
6	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, The, 2021, 397, 99-111.	13.7	3,887
7	Estimation of absorbed radiation doses to skin and Sâ€values for organs at risk due to nasal administration of PET agents using Monte Carlo simulations. Medical Physics, 2021, 48, 871-880.	3.0	2
8	MRI-guided histology of TDP-43 knock-in mice implicates parvalbumin interneuron loss, impaired neurogenesis and aberrant neurodevelopment in amyotrophic lateral sclerosis-frontotemporal dementia. Brain Communications, 2021, 3, fcab114.	3.3	11
9	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV,the, 2021, 8, e474-e485.	4.7	190
10	N-methyl-D-aspartate receptor availability in first-episode psychosis: a PET-MR brain imaging study. Translational Psychiatry, 2021, 11, 425.	4.8	14
11	Resolving the cellular specificity of TSPO imaging in a rat model of peripherally-induced neuroinflammation. Brain, Behavior, and Immunity, 2021, 96, 154-167.	4.1	16
12	Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet, The, 2021, 398, 856-869.	13.7	430
13	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nature Medicine, 2021, 27, 2032-2040.	30.7	900
14	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet, The, 2021, 398, 981-990.	13.7	214
15	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet, The, 2020, 396, 1979-1993.	13.7	1,196
16	Effects of the putative lithium mimetic ebselen on pilocarpine-induced neural activity. European Journal of Pharmacology, 2020, 883, 173377.	3.5	5
17	A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania. Psychopharmacology, 2020, 237, 3773-3782.	3.1	41
18	Region-specific and dose-specific effects of chronic haloperidol exposure on [3H]-flumazenil and [3H]-Ro15-4513 GABAA receptor binding sites in the rat brain. European Neuropsychopharmacology, 2020, 41, 106-117.	0.7	12

Nisha Singh

#	Article	IF	CITATIONS
19	T209. EFFECTS OF CHRONIC HALOPERIDOL EXPOSURE ON [3H]RO15-4513 AND [3H]FLUMAZENIL GABA-A RECEPTOR BINDING SITES. Schizophrenia Bulletin, 2020, 46, S312-S312.	4.3	0
20	Radiolabeling of [¹¹ C]FPS-ZM1, a receptor for advanced glycation end products-targeting positron emission tomography radiotracer, using a [¹¹ C]CO ₂ -to-[¹¹ C]CO chemical conversion. Future Medicinal Chemistry, 2020, 12, 511-521.	2.3	15
21	Investigating the effects of ebselen, a potential new lithium mimetic, on glutamate transmission. Synapse, 2020, 74, e22151.	1.2	5
22	Evaluation of [13N]ammonia positron emission tomography as a potential method for quantifying glutamine synthetase activity in the human brain. EJNMMI Research, 2020, 10, 146.	2.5	1
23	CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice. Brain, 2019, 142, 3243-3264.	7.6	156
24	Development of [18F]FAMTO: A novel fluorine-18 labelled positron emission tomography (PET) radiotracer for imaging CYP11B1 and CYP11B2 enzymes in adrenal glands. Nuclear Medicine and Biology, 2019, 68-69, 14-21.	0.6	22
25	Comment on " <i>In Vivo</i> [¹⁸ F]GE-179 Brain Signal Does Not Show NMDA-Specific Modulation with Drug Challenges in Rodents and Nonhuman Primates†ACS Chemical Neuroscience, 2019, 10, 768-772.	3.5	11
26	Plasma glutathione suggests oxidative stress is equally present in early―and lateâ€onset bipolar disorder. Bipolar Disorders, 2019, 21, 61-67.	1.9	10
27	Kinetic modelling of [¹¹ C]PBR28 for 18 kDa translocator protein PET data: A validation study of vascular modelling in the brain using XBD173 and tissue analysis. Journal of Cerebral Blood Flow and Metabolism, 2018, 38, 1227-1242.	4.3	51
28	GABA _A receptor availability is not altered in adults with autism spectrum disorder or in mouse models. Science Translational Medicine, 2018, 10, .	12.4	41
29	Assessing the feasibility of intranasal radiotracer administration for in brain PET imaging. Nuclear Medicine and Biology, 2018, 66, 32-39.	0.6	7
30	High-yielding ¹⁸ F radiosynthesis of a novel oxytocin receptor tracer, a probe for nose-to-brain oxytocin uptake <i>in vivo</i> . Chemical Communications, 2018, 54, 8120-8123.	4.1	28
31	[P4–509]: DEVELOPMENT AND EVALUATION OF A NOVEL POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR IMAGING THE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1536.	0.8	2
32	Effects of the potential lithium-mimetic, ebselen, on impulsivity and emotional processing. Psychopharmacology, 2016, 233, 2655-2661.	3.1	67
33	Effects of the potential lithium-mimetic, ebselen, on brain neurochemistry: a magnetic resonance spectroscopy study at 7 tesla. Psychopharmacology, 2016, 233, 1097-1104.	3.1	49
34	Effect of the Putative Lithium Mimetic Ebselen on Brain Myo-Inositol, Sleep, and Emotional Processing in Humans. Neuropsychopharmacology, 2016, 41, 1768-1778.	5.4	85
35	Scaffold Hopping with Virtual Screening from IP ₃ to a Drugâ€Like Partial Agonist of the Inositol Trisphosphate Receptor. ChemBioChem, 2014, 15, 2774-2782.	2.6	8
36	Altered plasma glutathione levels in bipolar disorder indicates higher oxidative stress; a possible risk factor for illness onset despite normal brain-derived neurotrophic factor (BDNF) levels. Psychological Medicine, 2014, 44, 2409-2418.	4.5	64

NISHA SINGH

#	Article	IF	CITATIONS
37	A safe lithium mimetic for bipolar disorder. Nature Communications, 2013, 4, 1332.	12.8	221
38	Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) Is a Second Messenger in Muscarinic Receptor-induced Contraction of Guinea Pig Trachea. Journal of Biological Chemistry, 2013, 288, 10986-10993.	3.4	16
39	Relating mood to plasma glutathione and BDNF levels in patients with bipolar disorder. FASEB Journal, 2013, 27, lb528.	0.5	0
40	Cloning, expression, purification, crystallization and X-ray analysis of inositol monophosphatase fromMus musculusandHomo sapiens. Acta Crystallographica Section F: Structural Biology Communications, 2012, 68, 1149-1152.	0.7	14